Clinical data | |
---|---|
Trade names | Clarinex, Aerius, Allex, others[1] |
Other names | descarboethoxyloratadine[2] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602002 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Rapidly absorbed |
Protein binding | 83 to 87% |
Metabolism | UGT2B10, CYP2C8 |
Metabolites | 3-Hydroxydesloratadine |
Onset of action | within 1 hour[6] |
Elimination half-life | 27 hours,[6] 33.7 hours in elderly patients[3] |
Duration of action | up to 24 hours[6] |
Excretion | 40% as conjugated metabolites into urine Similar amount into the feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.554 |
Chemical and physical data | |
Formula | C19H19ClN2 |
Molar mass | 310.83 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Desloratadine. sold under the brand name Clarinex among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.[6]
It was patented in 1984 and came into medical use in 2001.[7] It was brought to the market in the US by Schering Corporation, later named Schering-Plough.[3]
loratadine is metabolized to descarboethoxyloratadine predominantly by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, by cytochrome P450 2D6 (CYP2D6).